Advertisement

Dissemination (Meeting Coverage)

IO-Only or in Chemo-IO Regimens NSCLC Subgroups

Immunotherapy (IO) + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic non-small cell lung cancer (NSCLC), with IO-only therapy approved only for PD-L1+ NSCLC. Patients with PD-L1 scores from...

Read More

The Insider’s Guide to ASCO 2021: Ovarian Cancer

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...

Read More

AAN 2021: Dual Tasking In Patients With MS

Patients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...

Read More

SABCS 2020: First Immunotherapy Combo Well-Tolerated

In an interim analysis of the first immunotherapy combination phase 1b trial with trastuzumab deruxtecan, safety results showed nivolumab with trastuzumab deruxtecan was well tolerated in patients with HER2-positive or HER2-low...

Read More

For latest news and updates
Email-id is invalid